Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 113, Issue 2, Pages 756-769
Publisher
Wiley
Online
2021-12-09
DOI
10.1111/cas.15236
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
- (2021) Nathan D. Mathewson et al. CELL
- Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
- (2021) Rong Tang et al. Frontiers in Immunology
- Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Gliomas
- (2021) Zheng Zhao et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Immunotherapy for Malignant Glioma: Current Status and Future Directions
- (2020) Hongxiang Wang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Immunotherapy for glioma: Current management and future application
- (2020) Shengchao Xu et al. CANCER LETTERS
- Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis
- (2020) You Zhai et al. Frontiers in Immunology
- Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma
- (2020) Yuanhao Chang et al. Frontiers in Immunology
- Clinical practice guidelines for the management of adult diffuse gliomas
- (2020) Tao Jiang et al. CANCER LETTERS
- CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up
- (2019) Scott R Gilles et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma
- (2019) Zhi-liang Wang et al. Frontiers in Immunology
- Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
- (2019) Guan-Zhang Li et al. OncoTargets and Therapy
- Current state of immunotherapy for glioblastoma
- (2018) Michael Lim et al. Nature Reviews Clinical Oncology
- CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
- (2018) Stephen J Bagley et al. NEURO-ONCOLOGY
- Immunotherapies for malignant glioma
- (2017) Vassiliki A. Boussiotis et al. ONCOGENE
- Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
- (2017) Guanzhang Li et al. OncoImmunology
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- Emerging treatment strategies for glioblastoma multiforme
- (2014) S. K. Carlsson et al. EMBO Molecular Medicine
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started